DOCSLIB.ORG

Chapter 420-7-2 Controlled Substances

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Chapter 420-7-2 Controlled Substances Health Chapter 420-7-2 ALABAMA STATE BOARD OF HEALTH ALABAMA DEPARTMENT OF PUBLIC HEALTH ADMINISTRATIVE CODE CHAPTER 420-7-2 CONTROLLED SUBSTANCES TABLE OF CONTENTS 420-7-2-.01 Authority 420-7-2-.02 Definitions 420-7-2-.11 Prescription Drug Monitoring Program – Collection Of Fees To Support Database 420-7-2-.12 Prescription Drug Monitoring Program Reporting To Database By Dispensers 420-7-2-.13 Access To Database Appendix Controlled Substances List 420-7-2-.01 Authority. (1) The Alabama Controlled Substances List, shown as Appendix to this Chapter, comprises a complete listing of said substances, pursuant to Code of Ala. 1975, Sections 20-2-1, et seq. (2) The Controlled Substances List shall be published annually, reflecting the date of adoption and the effective date. (3) As substances are designated, rescheduled or deleted as controlled substances, the appendix and other publications shall be amended accordingly by adding to said listing a slip-sheet of the action taken and the effective date. Each annual publication, as provided in (2) above, will contain any amendment occurring during that year. Author: Alabama Department of Public Health Statutory Authority: Code of Ala. 1975, §§20-2-1, et seq. History: Filed September 1, 1982. 420-7-2-.02 Definitions. Supp. 12/31/16 7-2-1 Chapter 420-7-2 Health (1) Controlled Substance. A drug, substance or immediate precursor in Schedules I through V of Rule 420-7-2-.03 of this Chapter. (2) Drug. (a) Substances recognized as drugs in the official United States pharmacopoeia, official homeopathic pharmacopoeia of the United States or official national formulary or any supplement to any of them; (b) Substances intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease in man or animals; (c) Substances (other than food) intended to affect the structure or any function of the body of man or animals; and (d) Substances intended for use as a component of any article specified in paragraphs (a), (b) or (c) of this subdivision. Such term does not include devices or their components, parts or accessories. (3) Immediate Precursor. A substance which the State Board of Pharmacy has found to be and by rule designates as being the principal compound commonly used or produced primarily for use and which is an immediate chemical intermediary used or likely to be used in the manufacture of a controlled substance, the control of which is necessary to prevent, curtail or limit manufacture. (4) Marihuana. All parts of the plant Cannabis sativa L., whether growing or not, the seeds thereof, the resin extracted from any part of the plant and every compound, manufacture, salt, derivative, mixture or preparation of the plant, its seeds or resin. Such term does not include the mature stalks of the plant, fiber produced from the stalks, oil or cake made from the seeds of the plant, any other compound, manufacture, salt, derivative, mixture or preparation of the mature stalks (except the resin extracted therefrom), fiber, oil or cake or the sterilized seed of the plant which is incapable of germination. (5) Narcotic Drug. Any of the following, whether produced directly or indirectly by extraction from substances of Supp. 12/31/16 7-2-2 Health Chapter 420-7-2 vegetable origin or independently by means of chemical synthesis or by a combination of extraction and chemical synthesis: (a) Opium and opiate and any salt, compound, derivative or preparation of opium or opiate. (b) Any salt, compound, isomer, derivative or preparation thereof which is chemically equivalent or identical with any of the substances referred to in paragraph (a), but not including the isoquinoline alkaloids of opium. (c) Opium poppy and poppy straw. (d) Coca leaves and any salt, compound, derivative or preparation of coca leaves and any salt, compound, isomer, derivative or preparation thereof which is chemically equivalent or identical with any of these substances, but not including decocainized coca leaves or extractions of coca leaves which do not contain cocaine or ecgonine. (6) Opiate. Any substance having an addiction-forming or addiction-sustaining liability similar to morphine or being capable of conversion into a drug having addiction-forming or addiction sustaining liability. Such term does not include, unless specifically designated as controlled under this section, the dextrorotatory isomer of 3-methoxy-n-methylmorphinan and its salts (dextromethorphan). Such term does include its racemic and levorotatory forms. (7) Opium Poppy. The plant of the species Papaver somniferum L., except its seeds. (8) Poppy Straw. All parts, except the seeds, of the opium poppy, after mowing. Author: Alabama Department of Public Health Statutory Authority: Code of Ala. 1975, §§20-2-1, et seq. History: Filed September 1, 1982. 420-7-2-.11 Prescription Drug Monitoring Program - Collection Of Fees To Support The Database. (1) Act No. 2004-443 requires that the following licensing boards shall assess a surcharge in the amount of $10.00 per year on the controlled substance registration Supp. 12/31/16 7-2-3 Chapter 420-7-2 Health certificate issued or renewed each year to a licensee of the respective boards in the State of Alabama. This requirement is to be implemented effective October 12, 2004. A list of the affected licensing boards follows: (a) Alabama State Board of Medical Examiners (b) Alabama Board of Optometry (c) Alabama Board of Dental Examiners (d) Alabama State Board of Veterinary Medical Examiners (e) Alabama State Board of Podiatry (2) By the 10th of each quarter, each affected licensing board shall remit payment of $10.00 for each controlled substance registration certificate issued or renewed. The remittance shall be made payable to the Alabama Department of Public Health, Office of Professional and Support Services. (3) By October 30 of succeeding years, each affected licensing board shall certify the number of controlled substance registration certificates issued or renewed during the prior fiscal year. The certification shall be made to the Alabama Department of Public Health, Office of Professional and Support Services. (4) Funds remitted to the Alabama Department of Public Health pursuant to this section shall be deposited into the Alabama State Controlled Substance Database Trust Fund. The funds shall be used exclusively for the development, implementation, operation, and maintenance of the controlled substances prescription database. Author: Charles C. Thomas, R.Ph., State Pharmacy Director Statutory Authority: Code of Ala. 1975, §§22-21-20, et. seq. History: New Rule: Filed February 18, 2005; effective March 25, 2005. 420-7-2-.12 Prescription Drug Monitoring Program Reporting To Database By Dispensers. Supp. 12/31/16 7-2-4 Health Chapter 420-7-2 (1) Entities and practitioners that dispense controlled substances, Class II-V, shall report controlled substances prescription information to the Prescription Drug Monitoring Program database. These entities and practitioners include but are not limited to: (a) Licensed pharmacies; (b) Mail order pharmacies or pharmacy benefit programs filling prescriptions for or dispensing controlled substances to residents of Alabama; and (c) Licensed physicians, dentists, podiatrists, and optometrists who dispense controlled substances. (2) The reporting requirement in this rule does not apply to a controlled substance dispensed: (a) By a pharmacy of a hospital, nursing home, or other inpatient health care facility if administered and used by a patient on the facility’s premises; (b) By a practitioner if administered during the course of a patient’s treatment by injection, topical application, suppository administration, or oral administration; or (c) By a practitioner as an appropriately labeled sample medication. (3) Entities and practitioners shall submit reports as follows: (a) Entities shall submit reports at least once daily by 11:59 p.m. 1. If an entity or practitioner does not dispense a controlled substance on a specific day, the entity or practitioner shall report that zero controlled substances were dispensed. 2. The daily reporting requirement does not apply on days that the entity or practitioner’s business is closed and no controlled substances are dispensed. Supp. 12/31/16 7-2-5 Chapter 420-7-2 Health (b) Reports must be in electronic format according to American Society for Automation in Pharmacy Standards using the U.S. Postal Service’s Postal Addressing Standards. 1. If electronic transmission is not feasible, an entity or practitioner may request a waiver. 2. An entity or practitioner who receives a waiver may submit prescription information in an alternate format approved by the Prescription Drug Monitoring Program. 3. Entities and practitioners shall submit waiver requests and reports formatted pursuant to a valid waiver to: Alabama Department of Public Health Prescription Drug Monitoring Program The RSA Tower, Suite 1010 P.O. Box 303017 Montgomery, AL 36130-3017 Fax: (334) 206-5663 4. Penalties for noncompliance/non-reporting: (a) On a monthly basis or as designated by the Prescription Drug Monitoring Program, licensing boards shall supply an electronic listing to the Prescription Drug Monitoring Program of entities and practitioners required to report controlled substances. (b) The Prescription Drug Monitoring Program will monitor the list of entities and practitioners provided by the licensing boards for compliance in reporting to the database. (c) The Department will notify the appropriate licensing board of an entity or practitioner’s failure to report. Upon notification of a non-reporting entity or practitioner, the relevant licensing board shall investigate and report to the Department the outcome. Author: Nancy Bishop, R. Ph., State Pharmacy Director Statutory Authority: Code of Ala. 1975, §22-21-20, et. seq. History: New Rule: Filed October 20, 2005; effective November 24, 2005. Amended: Filed February 17, 2006; effective March 24, 2006. Amended: Filed October 20, 2014; effective November 24, 2014. Amended: Filed August 19, 2016; effective October 3, 2016. Supp. 12/31/16 7-2-6 Health Chapter 420-7-2 420-7-2-.13 Access To Database.
Load more

Recommended publications
  • Nové Rekreační Drogy
    Neurotoxikologie nových „legálních rekreačních drog“ ze skupin empatogenů/entaktogenů a disociativ MUDr. S. Zakharov, CSc. Toxikologické informa ční st ředisko1 Klinika pracovního léka řství Nové rekrea ční drogy („Legal Highs“) - pojem • Nové syntetické psychoaktivní látky neuvedené v Jednotné Úmluv ě o omamných látkách, v zákonu č. 167/1998 Sb.; • Prodávají se legáln ě přes internet („smartshops“, „rostliny- zahrada-online“, „výzkumné chemikálie“, e-inzeráty, aj.) • „Je to jako hra na chemickou ruskou ruletu, protože nejsou údaje o toxicit ě, biometabolitech, fakrmakokinetice…“ (John W. Huffman) • „Clubbers‘ drugs“ – používají ~40% návštěvníků no čních klub ů •Účinky: stimulanty, empatogeny/entaktogeny, halucinogeny (psychedelika, delirianty, disociativa), sedativa, a kombinace… 2 Nové rekrea ční drogy • Výroba v Jihovýchodní Asii, Číně, balení a distribuce v Evropě a Spojených Státech. • Jednoduchá schémata syntézy (2-3 chemické reakce, běžné reagens (toluen, aceton...), vysoká stupe ň chemické čistoty (99%), nízké ceny; • Chemická struktura je podobná struktuře zakázaných (kontrolovaných) psychoaktivních látek; • „Výzkumné chemikálie“ seznam.cz –– 51 odkaz; google.cz – 82 700 odkaz ů; • www.bulkresearchchemicals.com; http://vip- 3 legals.com; www.buyanychem.com MDMA („Extáze“, éčko, koláč) – 3,4- MetylenDioxy-N-Metyl Amfetamin) • Syntezována v r. 1912 (A.Kollisch, Merck), rekrea ční použití od r. 1963, zákaz - 1985 (SZO, USA). • „Droga lásky“: empatogen ( R. Metzner, 1983) nebo entaktogen ( D. Nichols, 1986) - indukce pocit ů empatie, vcítění, soudružnosti, lásky, emoční blízkosti. • MDMA-asistovaná psychoterapie v léčbě posttraumatických stresových poruch (PTSD), (výzkum sponzorován MAPS USA (Multidisciplinary Association For Psychedelic Studies). • V ČR „malé množství“ – do 4 tbl. (400 mg). 4 Mechanismus účinku a toxicita MDMA • Efektivně uvol ňuje a inhibuje zpětné vychytávání SER (afinita k presynaptic- kému SERT), méně – DAT, NAT • Mírně nespecificky inhibuje MAO (A, B) • Mírný agonista 5-HT2-Re (změna percepce), DA2- Re (euforia), NA-Re (symp-mim.
    [Show full text]
  • Prohibited Chemical Cn Ver4.00.Xlsx
    修订日：2021/7/15 Nitto集团 禁止含有的化学物质 Ver 4.00 分析 备注 物质 化学物质或物质群 阈值 数据 (记载的法律法规只用于对象物质的特定， 例举表 要否 其适用范围不作参考) (不使用保证书中收录的物质) EU REACH法规 AnnexⅩⅦ 未有意添加，且含量不超过1000ppm（不包 石棉类 需要 需要分析的仅限于滑石等可能有石棉混入的 表A 括1000ppm） 矿物原料 ― 部分偶氮染料/颜料（生成特定胺） 未有意添加 EU REACH法规 AnnexⅩⅦ 未有意添加，且镉含量不超过 镉及其化合物 需要 2011/65/EU(EU RoHS2指令) ５ppm（不包括5ppm） 未有意添加，且六价铬含量不超过 六价铬化合物 需要 2011/65/EU(EU RoHS2指令) 100ppm（不包括100ppm） 未有意添加，且铅含量不超过100ppm（不包 铅及其化合物 需要 2011/65/EU(EU RoHS2指令) 括100ppm） 未有意添加，且汞含量不超过100ppm（不包 汞及其化合物 需要 2011/65/EU(EU RoHS2指令) 括100ppm） 未有意添加，且PBB含量不超过100ppm（不 多溴联苯类（PBB类） 需要 2011/65/EU(EU RoHS2指令) 包括100ppm） 未有意添加，且PBDE含量不超过100ppm（不 2011/65/EU(EU RoHS2指令) 多溴联苯醚类（PBDE类） 需要 包括100ppm） 包括十溴联苯醚 蒙特利尔议定书 臭氧层破坏物质 未有意添加 ― 同时禁止在制造工序中使用 未有意添加，且含量不超过1000ppm（不包 邻苯二甲酸（2-乙基己基）酯(DEHP) 需要 2011/65/EU(EU RoHS2指令) 括1000ppm） 未有意添加，且含量不超过1000ppm（不包 邻苯二甲酸二正丁酯(DBP) 需要 2011/65/EU(EU RoHS2指令) 括1000ppm） 未有意添加，且含量不超过1000ppm（不包 邻苯二甲酸丁基苄酯(BBP) 需要 2011/65/EU(EU RoHS2指令) 括1000ppm） 未有意添加，且含量不超过1000ppm（不包 邻苯二甲酸二异丁酯(DIBP) 需要 2011/65/EU(EU RoHS2指令) 括1000ppm） 斯德哥爾摩公約 Annex A 多氯联苯类（PCB类） 未有意添加 ― 第一种特定化学物质（日本 化学物质的审 查及制造等的规制法）（以下简称化审法） 多氯三联苯类（PCT类） 未有意添加 ― EU REACH法规 AnnexⅩⅦ ― 多氯萘（氯原子数大于等于2） 未有意添加 化审法第一种特定化学物质 放射性物质 未有意添加 ― 使用放射性同位素的分析仪器除外 ― 斯德哥爾摩公約 Annex A 短链氯化石蜡（C10－C13） 未有意添加 化审法第一种特定化学物质 EU REACH法规 AnnexⅩⅦ 三丁基氧化锡（TBTO） 未有意添加 ― 化审法第一种特定化学物质 未有意添加，且含量不超过25ppb（不包括 全氟辛酸（PFOA）和其盐类及其PFOA的相关物 POPs公约 Annex A 25ppb）（PFOA相关物质不超过1000ppb） ― 质 EU POPs规则 附属书1 （不包括1000ppb） 未有意添加，且含量不超过25ppb（不包括 全氟乙基磺酸(PFHxS)及其盐类及PFHxS 相关 25ppb）（PFHxS相关物质不超过1000ppb） ― POPs公约 Annex A 物质 （不包括1000ppb） 三取代有机锡化合物 EU REACH法规 AnnexⅩⅦ 未有意添加 ― （包括TBT类、TPT类）（注1）
    [Show full text]
  • Article 22 Regulation for Restriction of Synthetic Drugs
    ARTICLE 22 REGULATION FOR RESTRICTION OF SYNTHETIC DRUGS SECTION 22.1 AUTHORITY This regulation is promulgated under the authority granted to the Needham Board of Health under Massachusetts General Laws Chapter 111, Section 31 which states that “boards of health may make reasonable health regulations”. SECTION 22.2 PURPOSE The Needham Board of Health has found that synthetic marijuana, consisting of plant or other material treated with various chemicals or other synthetic substances not approved for human consumption, may be marketed and sold as herbal incense in the greater Boston area, although they are being used in the same manner and for the same purposes as scheduled drugs. In addition, the use of these products has become particularly popular among teens and young adults. Based on information and reports from hospitals, emergency room doctors, and police agencies, individuals who use these products experience dangerous side effects including convulsions, hallucinations, and dangerously elevated heart rates. This is evidence that synthetic marijuana products are harmful if inhaled or consumed, and present a significant public health danger. These synthetic compounds and others have a high potential for abuse and lack of any accepted medical use, these dangerous products, while not approved for human consumption, are marketed and sold in a form that allows for such consumption, putting at risk the individuals who come into contact with them. Therefore, the Needham Board of Health adopts this regulation for the purpose and with the intent to protect the public health and safety of the Town of Needham and its residents from the threat posed by the availability and use of synthetic marijuana, synthetic stimulants, synthetic hallucinogens, and other dangerous products by prohibiting persons from trafficking in, possessing, and using them within the town.
    [Show full text]
  • General Drug and Explosive Detection
    Ζ'HQWDȇV'UXJ'HWHFWLRQDQGΖGHQWLILFDWLRQWHVWNLWVRIIHUEUHDNWKURXJKLQQRYDWLRQVORQJ DZDLWHGE\WKHIRUHQVLFPDUNHW8QWLOUHFHQWO\RQO\GLIILFXOWWRXVHDQGKDUGWRXQGHUVWDQG WHVWNLWVZLWKPDQ\FRQVWUDLQWVDQGOLPLWDWLRQVZHUHDYDLODEOHΖ'HQWDȇVNLWVPDNHWKH WDVNVIDFHGE\SDUHQWVHGXFDWRUVHPSOR\HUVDQGODZHQIRUFHPHQWRIILFHUVHDVLHU IDVWHUIDUVDIHUDQGPRUHFRVWHIIHFWLYHWKDQDQ\VLPLODUNLWDYDLODEOH .H\%HQHILWV .H\0DUNHWV ႑(DV\IDVWDQGVLPSOHWRXVH1RRWKHUWHVWVDUH ႑/DZHQIRUFHPHQW DVVWUDLJKWIRUZDUG ႑0LOLWDU\ ႑$FFXUDWHDQGUHOLDEOHDWH[WUHPHWHPSHUDWXUHV ႑&XVWRPV ႑&OHDUUHVXOWVLQVHFRQGV ႑6HFXULW\DJHQFLHV ႑/RQJVKHOIOLIH XSWR\HDUV ZLWKQRVWRUDJH ႑*RYHUQPHQWDJHQFLHV UHVWULFWLRQV ,'7 '($)%Ζ&Ζ$ ,'7 ,'7 ႑6DIH$FWXDOO\YHU\VDIH1RFRQWDFWZLWK *HQHUDO6FUHHQLQJ ႑3ULVRQV FKHPLFDOVRUVXEVWDQFHV1RLQKDODWLRQRI .HWDPLQH /LTXLG *+% 'UXJV &RUSRUDWH+5GHSDUWPHQWV YDSRUVQRSURWHFWLYHJHDUQHHGHG ႑ ΖGHQWLILFDWLRQ ΖGHQWLILFDWLRQ ΖGHQWLILFDWLRQ ႑6DIHWRGLVSRVH6HOIFRQWDLQHGQHXWUDOL]DWLRQ ႑3ULYDWHUHVLGHQFHV )LHOG7HVW.LW ႑6PDOODQGYHU\UXJJHG ႑6FKRROV8QLYHUVLWLHV )LHOG7HVW.LW )LHOG7HVW.LW ႑&DQEHXVHGDQ\ZKHUHDQ\WLPH ႑5HKDELOLWDWLRQIDFLOLWLHV ႑7KHFRORUWHVWLVEDVHGRQWKHVDPHFKHPLVWU\DV ႑ƀ+\GUR[\EXW\ULFDFLG *+% LVDFHQWUDO ႑7KHWHVWGHWHFWVGUXJVLQFOXGLQJFRFDLQH ႑$YDLODEOHZLWKYDULRXVSUREHV ႑%RUGHUFRQWURO IRUWKHVROLGWHVW QHUYRXVV\VWHPGHSUHVVDQWXVHGDVDQ KHURLQDPSKHWDPLQHHFVWDV\DVZHOODVQHZ 7RXFK6ZLSH6QLIIHURU6DPSOHU LQWR[LFDQW GHVLJQHUGUXJV ႑(PHUJHQF\URRPV ႑7KHNLWFRQWDLQVDQRYHOVDPSOHUIRUWKHHDV\ ႑2XUNLWV'2WHVWOLTXLGV WHVWLQJRIOLTXLGV ႑&RPPRQVWUHHWQDPHVLQFOXGH*/LTXLG ႑7KHWHVWLVEDVHGRQDQRYHOFRORUWHVWIRU */LTXLG;/LTXLG(*HRUJLD+RPH%R\ DONDORLGV
    [Show full text]
  • Comprehensive Multi-Analytical Screening Of
    COMPREHENSIVE MULTI-ANALYTICAL SCREENING OF DRUGS OF ABUSE, INCLUDING NEW PSYCHOACTIVE SUBSTANCES, IN URINE WITH BIOCHIP ARRAYS APPLIED TO THE EVIDENCE ANALYSER Darragh J., Keery L., Keenan R., Stevenson C., Norney G., Benchikh M.E., Rodríguez M.L., McConnell R. I., FitzGerald S.P. Randox Toxicology Ltd., Crumlin, United Kingdom e-mail: [email protected] Introduction Biochip array technology allows the simultaneous detection of multiple drugs from a single undivided sample, which This study summarises the analytical performance of three different biochip arrays applied to the screening of increases the screening capacity and the result output per sample. Polydrug consumption can be detected and by acetylfentanyl, AH-7921, amphetamine, barbiturates, benzodiazepines (including etizolam and clonazepam), incorporating new immunoassays on the biochip surface, this technology has the capacity to adapt to the new trends benzoylecgonine/cocaine, benzylpiperazines, buprenorphine, cannabinoids, carfentanil, dextromethorphan, fentanyl, in the drug market. furanylfentanyl, meprobamate, mescaline, methamphetamine, methadone, mitragynine, MT-45, naloxone, ocfentanyl, opioids, opiates, oxycodone, phencyclidine, phenylpiperazines, salvinorin, sufentanil, synthetic cannabinoids (JWH-018, UR-144, AB-PINACA, AB-CHMINACA), synthetic cathinones [mephedrone, methcathinone, alpha- pyrrolidinopentiophenone (alpha-PVP)], tramadol, tricyclic antidepressants, U-47700, W-19, zolpidem. Methodology Three different biochip arrays were used (DOA ULTRA,
    [Show full text]
  • AGENDA Friday, September 9, 2016 7:00 A.M
    Needham Board of Health AGENDA Friday, September 9, 2016 7:00 a.m. – 9:00 a.m. Charles River Room – Public Services Administration Building 500 Dedham Avenue, Needham MA 02492 • 7:00 to 7:05 - Welcome & Review of Minutes (July 29 & August 29) • 7:05 to 7:30 - Director and Staff Reports (July & August) • 7:30 to 7:45 - Discussion about Proposed Plastic Bag Ban Christopher Thomas, Needham Resident • 7:45 to 7:50 - Off-Street Drainage Bond Discussion & Vote • 7:50 to 8:00 - Update on Wingate Pool Variance Application * * * * * * * * * * * * * Board of Health Public Hearing • 8:00 to 8:40 - Hearing for Proposed New or Amended BOH Regulations o Body Art o Synthetic Marijuana o Drug Paraphernalia • 8:40 to 8:50 - Board Discussion of Policy Positions • Other Items (Healthy Aging, Water Quality) • Next Meeting Scheduled for Friday October 14, 2016 • Adjournment (Please note that all times are approximate) 1471 Highland Avenue, Needham, MA 02492 781-455-7500 ext 511 (tel); 781-455-0892 (fax) E-mail: [email protected] Web: www.needhamma.gov/health NEEDHAM BOARD OF HEALTH July 29, 2016 MEETING MINUTES PRESENT: Edward V. Cosgrove, PhD, Chair, Jane Fogg, Vice-Chair, M.D., and Stephen Epstein, M.D STAFF: Timothy McDonald, Director, Donna Carmichael, Catherine Delano, Maryanne Dinell, Tara Gurge GUEST: Kevin Mulkern, Aquaknot Pools, Inc., Keith Mulkern, Aquaknot Pools, Inc., David Friedman, Wingate, Paul Humphreys, Michael Tomasello, Callahan, Inc. CONVENE: 7:00 a.m. – Public Services Administration Building (PSAB), 500 Dedham Avenue, Needham MA 02492 DISCUSSION: Call To Order – 7:06 a.m. – Dr. Cosgrove, Chairman APPROVE MINUTES: Upon motion duly made and seconded, the minutes of the BOH meeting of June 17, 2016 were approved as submitted.
    [Show full text]
  • Aminoindanesthe Next Wave of Legal Highs?
    Drug Testing Review and Analysis Received: 23 May 2011 Accepted: 24 May 2011 Published online in Wiley Online Library: 11 July 2011 (www.drugtestinganalysis.com) DOI 10.1002/dta.318 Aminoindanes – the next wave of ‘legal highs’? P.D. Sainsbury,a A.T. Kicman,a R.P. Archer,b L.A. Kinga and R.A. Braithwaitea∗ Due to its closed ring system, 2-aminoindane is a conformationally rigid analogue of amphetamine. Internet websites offering synthetic compounds as ‘research chemicals’ have recently been advertising 5,6-methylenedioxy-2-aminoindane (MDAI), 5, 6-methylenedioxy-N-methyl-2-aminoindane (MDMAI), 5-iodo-2-aminoindane (5-IAI), and 5-methoxy-6-methyl-2-aminoindane (MMAI). The chemistry, pharmacology, and toxicological aspects of this new class of psychoactive substances are reviewed, as these could become the next wave of ‘legal highs’. Copyright c 2011 John Wiley & Sons, Ltd. Keywords: aminoindanes; legal highs; MDAI; MDMAI; 5-IAI; MMAI; serotonin. Introduction Pharmacology Although Solomons and Sam reported in 1973 that the aminoin- Historically, the terms ‘legal highs’ and ‘herbal highs’ referred to danes possessed significant bronchodilating and analgesic blends of psychoactive plants or fungi that could be smoked properties,[2] more recent research points to the aminoindanes as or ingested to induce dissociative effects and hallucinations. having potent effects on serotonin release and re-uptake. A num- These terms, however, have more recently been widened to ber of studies undertaken in the late 1980s and early 1990s con- describe an extensive and growing range of entirely synthetic cerning Ecstasy (3,4-methylenedioxymethamphetamine; MDMA) substances that have become popular as recreational drugs of also included a comparison with a number of MDMA analogues abuse; this coincides with a period of intense media interest that incorporated an indane ring.
    [Show full text]
  • Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances Joshua Zolton Seither [email protected]
    Florida International University FIU Digital Commons FIU Electronic Theses and Dissertations University Graduate School 4-25-2018 Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances Joshua Zolton Seither [email protected] DOI: 10.25148/etd.FIDC006565 Follow this and additional works at: https://digitalcommons.fiu.edu/etd Part of the Chemistry Commons Recommended Citation Seither, Joshua Zolton, "Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances" (2018). FIU Electronic Theses and Dissertations. 3823. https://digitalcommons.fiu.edu/etd/3823 This work is brought to you for free and open access by the University Graduate School at FIU Digital Commons. It has been accepted for inclusion in FIU Electronic Theses and Dissertations by an authorized administrator of FIU Digital Commons. For more information, please contact [email protected]. FLORIDA INTERNATIONAL UNIVERSITY Miami, Florida APPLICATION OF HIGH RESOLUTION MASS SPECTROMETRY FOR THE SCREENING AND CONFIRMATION OF NOVEL PSYCHOACTIVE SUBSTANCES A dissertation submitted in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY in CHEMISTRY by Joshua Zolton Seither 2018 To: Dean Michael R. Heithaus College of Arts, Sciences and Education This dissertation, written by Joshua Zolton Seither, and entitled Application of High- Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances, having been approved in respect to style and intellectual content, is referred to you for judgment. We have read this dissertation and recommend that it be approved. _______________________________________ Piero Gardinali _______________________________________ Bruce McCord _______________________________________ DeEtta Mills _______________________________________ Stanislaw Wnuk _______________________________________ Anthony DeCaprio, Major Professor Date of Defense: April 25, 2018 The dissertation of Joshua Zolton Seither is approved.
    [Show full text]
  • Model Scheduling New/Novel Psychoactive Substances Act (Third Edition)
    Model Scheduling New/Novel Psychoactive Substances Act (Third Edition) July 1, 2019. This project was supported by Grant No. G1799ONDCP03A, awarded by the Office of National Drug Control Policy. Points of view or opinions in this document are those of the author and do not necessarily represent the official position or policies of the Office of National Drug Control Policy or the United States Government. © 2019 NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. This document may be reproduced for non-commercial purposes with full attribution to the National Alliance for Model State Drug Laws. Please contact NAMSDL at [email protected] or (703) 229-4954 with any questions about the Model Language. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: NATIONAL ALLIANCE FOR MODEL STATE DRUG 1 LAWS, 1335 North Front Street, First Floor, Harrisburg, PA, 17102-2629. Model Scheduling New/Novel Psychoactive Substances Act (Third Edition)1 Table of Contents 3 Policy Statement and Background 5 Highlights 6 Section I – Short Title 6 Section II – Purpose 6 Section III – Synthetic Cannabinoids 13 Section IV – Substituted Cathinones 19 Section V – Substituted Phenethylamines 23 Section VI – N-benzyl Phenethylamine Compounds 25 Section VII – Substituted Tryptamines 28 Section VIII – Substituted Phenylcyclohexylamines 30 Section IX – Fentanyl Derivatives 39 Section X – Unclassified NPS 43 Appendix 1 Second edition published in September 2018; first edition published in 2014. Content in red bold first added in third edition. © 2019 NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. This document may be reproduced for non-commercial purposes with full attribution to the National Alliance for Model State Drug Laws.
    [Show full text]
  • CREW NPS Booklet
    NEW Psychoactive DRUGS V1.7 05/15 Service availability Drop-in: Monday – Wednesday: 1pm – 5pm, Thursday: 3pm – 7pm, Friday – Saturday: 1pm – 5pm, Sunday: Closed Telephone information and support: Monday – Friday: 10am – 5pm Online information and chatroom support: www.mycrew.org.uk Address | 32 Cockburn Street | Edinburgh | EH1 1PB Telephone | 0131 220 3404 Email | [email protected] Main | www.crew2000.org.uk Enterprise | www.mindaltering.co.uk Info and support | www.mycrew.org.uk Facebook | www.facebook.com/Crew2000 Twitter | www.twitter.com/Crew_2000 Instagram | www.instagram.com/Crew_2000 This booklet has been designed to expand worker knowledge and confidence in the area of NPS. It is most useful when discussed as part of Crew’s NPS training. Crew was established in 1992, in response to the rapid expansion of recreational drug use. We provide up-to-date information on the drugs that people are taking so they can make informed decisions about their own health. This is achieved using a stepped care approach and through collaboration with volunteers, service users and professionals. Crew neither condemns nor condones drug use, but we believe there are ways to reduce harm to health. As a national agency, Crew is at the forefront of emerging drug trends and we engage at all levels including service development, practice and policy. Our services include: – Support line: non-judgmental drug and sexual health information and support. – Drop-in: drug and sexual health information, condoms (NHS c:card service) and DJ workshops. – Outreach services: we provide welfare at large events, such as clubs and festivals to educate revellers on partying safely.
    [Show full text]
  • Guidance on the Clinical Management of Acute and Chronic Harms of Club Drugs and Novel Psychoactive Substances NEPTUNE
    Novel Psychoactive Treatment UK Network NEPTUNE Guidance on the Clinical Management of Acute and Chronic Harms of Club Drugs and Novel Psychoactive Substances NEPTUNE This publication of the Novel Psychoactive Treatment UK Network (NEPTUNE) is protected by copyright. The reproduction of NEPTUNE guidance is authorised, provided the source is acknowledged. © 2015 NEPTUNE (Novel Psychoactive Treatment UK Network) 2015 Club Drug Clinic/CAPS Central and North West London NHS Foundation Trust (CNWL) 69 Warwick Road Earls Court SW5 9HB http://www.Neptune-clinical-guidance.com http://www.Neptune-clinical-guidance.co.uk The guidance is based on a combination of literature review and expert clinical con sensus and is based on information available up to March 2015. We accept no responsi bility or liability for any consequences arising from the use of the information contained in this document. The recommended citation of this document is: Abdulrahim D & Bowden-Jones O, on behalf of the NEPTUNE Expert Group. Guidance on the Management of Acute and Chronic Harms of Club Drugs and Novel Psychoactive Substances. Novel Psychoactive Treatment UK Network (NEPTUNE). London, 2015. NEPTUNE is funded by the Health Foundation, an independent charity working to improve the quality of health care in the UK. Editorial production and page design by Ralph Footring Ltd, http://www.footring.co.uk NEPTUNE NEPTUNE (Novel Psychoactive Treatment UK Network): Expert Group members NEPTUNE Expert Group Dr Owen Bowden-Jones Neptune Chair Clinical and programme lead Consultant
    [Show full text]
  • 2021 Il Mmai
    MeridianComplete (Medicare-Medicaid Plan) 2021 List of Covered Drugs (Formulary) Formulary ID: 21425 Version Number: 21 Updated on 8/24/2021. For more recent information or other questions, contact us at 1-855-580-1689 (TTY users should call 711). Representatives are available Monday-Friday, 8 a.m. to 8 p.m. to assist you. On weekends and on state or federal holidays, you may be asked to leave a message. Your call will be returned within the next business day. Or visit corp.mhplan.com/en/member/illinois/complete/. H6080_MMP_61396E_Accepted DIR053819ET00 H6080_MMP_61396E_Approved MeridianComplete | 2021 List of Covered Drugs (Formulary) Introduction This document is called the List of Covered Drugs (also known as the Drug List). It tells you which prescription drugs and over-the-counter drugs and items are covered by MeridianComplete (Medicare-Medicaid Plan). The Drug List also tells you if there are any special rules or restrictions on any drugs covered by MeridianComplete. Key terms and their definitions appear in the last chapter of the Member Handbook. Table of Contents A. Disclaimers ............................................................................................................................... 3 B. Frequently Asked Questions (FAQ) .......................................................................................... 4 B1. What prescription drugs are on the List of Covered Drugs? (We call the List of Covered Drugs the “Drug List” for short.) ........................................................................................
    [Show full text]